Egetis Therapeutics AB (publ) (FRA:P0F)

Market Cap	186.51M
Revenue (ttm)	5.01M
Net Income (ttm)	-30.15M
Shares Out	n/a
EPS (ttm)	-0.08
PE Ratio	n/a
Forward PE	18.93
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	5
Open	0.4245
Previous Close	0.4100
Day's Range	0.4245 - 0.4245
52-Week Range	0.2495 - 0.6090
Beta	n/a
RSI	47.64
Earnings Date	Nov 25, 2025

About Egetis Therapeutics AB

Egetis Therapeutics AB (publ), a pharmaceutical company, focuses on projects in late-stage development for the treatment of serious diseases with unmet medical needs in the orphan drug segment. The company’s products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol overdose, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of monocarboxylate transporter 8 (MCT8) deficiency, a debilitating rare disease with no available treatment. The company was ...

• Industry: Pharmaceutical Preparations
• Founded: 2006
• Employees: 40
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: P0F

Financial Performance

In 2024, Egetis Therapeutics AB's revenue was 46.10 million, a decrease of -19.97% compared to the previous year's 57.60 million. Losses were -343.60 million, 5.11% more than in 2023.

Financial numbers in SEK